Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Dr Barbara K Burton
Feinberg School of Medicine, Chicago, IL, USA
Dr Barbara K Burton is a professor of paediatrics at the Northwestern University Feinberg School of Medicine, and an attending physician in the Division of Genetics, Birth Defects and Metabolism at the Ann & Robert H. Lurie Children’s Hospital of Chicago, IL, USA. She is board certified in paediatrics, clinical genetics and clinical biochemical genetics. read more
Dr Burton’s clinical and research interests are focused on inborn errors of metabolism and newborn screening. She is an investigator in numerous natural history studies and clinical trials of new therapies for a wide range of metabolic disorders, including many lysosomal disorders. She has published over 300 peer-reviewed articles and 50 chapters in books, and is an editor of two textbooks.
Dr Burton is active in professional organizations and is a past president of the Society for Inherited Metabolic Disorders and the Chicago Pediatric Society. She served for 4 years as a member of the Secretary’s Advisory Committee on Heritable Disorders in Infants and Children, the federal advisory committee that makes recommendations regarding newborn screening in the US, and served for many years as chair of the Newborn Screening Advisory Committee of the Illinois Department of Public Health.
She is an emeritus member of the board of directors of the Greater Chicago Area March of Dimes and received a Lifetime Achievement Award from the March of Dimes in 2017. She received the PKU Hero Award from the National PKU Alliance in 2018 and the Legacy Award for Clinical Practice from the National MPS Society in 2024. She is a member of the scientific advisory board of the National MPS Society and serves on the medical advisory board of a number of other patient advocacy organizations.
Dr Barbara K Burton discloses: Advisory board/panel fees from Amgen, JCR Pharma, Moderna and Orchard. Consultancy fees from Alltrna, Chiesi, Passage Bio, Takeda and Ultragenyx. Speaker’s bureau fees from Amgen, Biomarin and Takeda.
Dr Can (John) Ficicioglu
Children’s Hospital of Philadelphia, Philadelphia, PA, USA
Dr Can (John) Ficicioglu is professor of paediatrics at the Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. He is director of the Biochemical Genetics section of the Newborn Metabolic Screening Program and Lysosomal Storage Disease Center at The Children’s Hospital of Philadelphia, USA. read more
Dr Ficicioglu received his MD and PhD from the University of Istanbul Medical School. He completed his residency at Montefiore Children’s Hospital and Genetics fellowship at Children’s Hospital Boston, Harvard Medical School. Dr Ficicioglu’s expertise encompasses newborn metabolic screening and lysosomal storage disorders. He is involved in clinical trials of new drugs to treat inborn errors of metabolism, such as lysosomal storage disorders and phenylketonuria, for which he has received several grants to support his clinical research.
Dr Ficicioglu has received multiple grants from the Pennsylvania and New Jersey states’ newborn screening programmes and from the National Institutes of Health (NIH), and funding from the pharmaceutical sector for registries and clinical trials (including gene therapies). His research has resulted in over 100 peer-reviewed journal articles, as well as significant contributions to scientific committees, with an emphasis on newborn screening and inborn errors of metabolism.
Dr Can (John) Ficicioglu discloses: Advisory board/panel fees from Chiesi (relationship terminated). Grant/research support fees from Denali Therapeutics, JCR Pharmaceuticals, Moderna, Passage Bio, Regenexbio and Trevena.
Dr Christina Lampe
University of Giessen, Giessen, Germany
Dr Christina Lampe is director of the Centre for Rare Diseases within the Department of Pediatric Neurology, Muscular Diseases, and Social Pediatrics at the University of Giessen, Germany. read more
After studying medicine at the Humboldt University of Berlin (Charité), she completed her internship in the Surgical Department of the same university. In 2007, Dr Lampe transitioned to the metabolic field and began working at Villa Metabolica in the Department of Pediatric and Adolescent Medicine at Johannes Gutenberg University of Mainz, Germany.
In January 2014, together with Prof. Maurizio Scarpa, Dr Lampe established a Centre for Rare Diseases at the Dr. Horst Schmidt Kliniken in Wiesbaden, Germany, primarily focused on lysosomal diseases and related disorders. In October 2018, she established the Center for Rare Diseases at the University Hospital in Giessen (ZSEGI), where she continues to care for a large number of paediatric and adult patients with lysosomal diseases and related conditions. Dr Lampe serves as both an investigator and co-investigator in several clinical trials concerning lysosomal diseases.
Dr Christina Lampe discloses: Advisory board/panel and consultancy fees from Alexion, Amicus, BioMarin, Chiesi, Sanofi and Takeda.
